Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
This study will collect data on safety, effectiveness and patient acceptance of MabCampath
 treatment under daily life conditions.
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was
 originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer
 Schering Pharma AG, Germany.
Inclusion Criteria:

 In- and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely
 monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath
 treatment and for at least 2 months following completion of treatment.

 Exclusion Criteria:

 In accordance with Summaries of Product Characteristics (SPC).